2cureX (2CUREX.ST) Stock Analysis & AI Equity Report
2cureX (2CUREX.ST) overview
2cureX (2CUREX.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, 2cureX reported revenue of SEK 0m and operating profit of SEK -4.7m; the year-end share price was 0.42 SEK and market capitalisation was SEK 8.9m. 2cureX is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get 2cureX's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About 2cureX
2cureX AB is a biotechnology company focused on functional precision oncology. It develops and commercialises the IndiTreat® family of cancer drug-sensitivity tests, which use patient tumour samples to create 3D tumoroids and help identify treatments likely to work for metastatic colorectal cancer. The company is also pursuing a revised commercial structure and broader indications.
Generate the 2cureX report
2cureX is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for 2cureX and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.